Pfizer: David M. Denton appointed as Chief Financial Officer and Executive Vice President

David M. Denton will join Pfizer as Chief Financial Officer and Executive Vice President effective May 2, 2022.

Denton will be a member of Pfizer’s Executive Leadership Team reporting to chairman and CEO, Albert Bourla. He joins Pfizer from Lowe’s Companies, Inc. where he served as CFO and Executive Vice President. Denton succeeds Frank D’Amelio, CFO and Executive Vice President, who recently announced his intention to leave Pfizer after a 15-year career. D’Amelio will remain in place through a transition period.

Denton has more than 25 years of finance and operational expertise, including more than 20 years in the healthcare sector. He will be a key thought partner to the Company’s CEO and Executive Leadership Team while overseeing every aspect of the Company’s financial management. He will be responsible for all corporate finance functions, including audit, treasury, tax, insurance, operations planning and analysis (OP&A), corporate controllership, and business finance and analytics.

Prior to joining Lowe's in 2018, Denton was CFP of CVS Health, where he was responsible for all aspects of their financial planning and management. He played a key role in CVS’s journey from a retail pharmacy to the health solutions company it is today and led the full integration of Caremark into CVS. In December 2017, Denton played a pivotal role in CVS’s acquisition of Aetna, structuring and negotiating the terms and financing for the transaction.

Before becoming CFO at CVS, Denton held several leadership roles, including senior vice president and controller/chief accounting officer. Prior to CVS, he was with the management consulting firm of Deloitte Touche Tohmatsu.

He earned a bachelor's degree in business administration from Kansas State University, USA and an MBA from the Babcock Graduate School of Management at Wake Forest University, USA. He serves on the board of Tapestry, Inc.